As of February 27, 2015, we have four full-time employees and four part-time employees. In addition, we have a number of consulting agreements for clinical development, regulatory affairs, investor relations and business development. We outsource all of our drug discovery research, process development, manufacturing and clinical development to third parties with expertise in those areas.
if you were a neural stem cell from person A and placed in person B, what is the incentive to stick to the host's spinal cord and differentiate to the neurons and why would you try to fill the gap of broken spinal cord? Why would the host B even accept the person A's cells as its own?
What do you all think
It is guaranteed, no matter now positive things are.
Even if they shorted at 5 and are sitting on a lot of gains, they have likely moved their gains on to other things, in order to let that money work for them, bit they are still on margin with zogenix and every time it goes up by a penny they have to pull 2 pennies from somewhere else to maintain margin and if they cover they will raise the price and hurt themselves by raising the rice. It is beginning to look like they are trapped for the next two years because it appears Z is not going to need any funding for two years. Greed got the better part of them when they didn't cover when the merger related panic selling ensued a few weeks ago, now it is too late.
I have two user profiles one for the one with the wife on it and one for without the wife. I suspect everyone has the same so user growth is meaningless...
what are you people smoking?
I am looking at the sunrise trial on drug trials dot gov. Do you know why all clinical sites that take patients are Peregrine and why they don't use universities and large clinics to collect patients?